Pharmafile Logo

Research Partnership ranks 13th in the top 20 fastest-growing agencies in the UK

February 4, 2019 | Pharma, healthcare, market research 

The UK’s best performing market research agencies were revealed earlier this month with the publication of Research Live’s Industry Report for 2019, which includes the latest Market Research Society (MRS) League Tables. Based on 2017 financial data that was compiled and analysed in November 2018, the MRS league tables identify and rank the best-performing research agencies and businesses according to their UK-based turnover and by their year-on-year growth.

With a growth rate of 21.87%, Research Partnership has been ranked 13th in the top 20 fastest-growing individual agencies. In addition, with over £27.5 million in sales, the company ranked 25th in the top 50 consolidated businesses, which draws agencies together under ownership groups, and 27th in the top 100 individual agencies, both of which are ranked by annual turnover.

Founding Director Mark Jeffery was interviewed for the report’s ‘Perspective from the Fastest Growers’ to find out how Research Partnership is achieving growth in an uncertain climate. Mark commented, “We are delighted to see Research Partnership placed so well in the league tables again this year. Our senior level and business development teams work hard to secure new clients, and our research teams ensure that we receive repeat business by delivering the very best service. We celebrated our 20th anniversary last year and have enjoyed consistent growth every year since we started. As a result we are now the largest independent healthcare market research agency in the world, working with all the major global pharma organisations.”

In the past year Research Partnership’s has also expanded into the medical technology space, built up the company’s market access capabilities, opened three new offices across the US and Europe, and grown the workforce by 15%.

Read the full report here »

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Understanding the Patient Journey

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology...